Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 20

In contrast to trastuzumab, pertuzumab

inhibits HRG-mediated HER2 signaling

ErbB2/ErbB3 co-ip

AKT

Agus DBm et al. Cancer Cell 2002

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,10,11,12,13,14,15,16,17,18,19 21,22,23,24,25,26,27,28,29,30,...47